Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4587 participants.
Also called NCT01422616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,587 participants
- Sponsor
- Registry
-
NCT01422616
-
- Main results
- Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
- Other papers using this trial's data
- Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study
- Body Weight in Relation to the Effectiveness of Intravenous Alteplase in Acute Ischemic Stroke: The ENCHANTED Trial
- Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial
- Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results
- Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial
- Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study
- Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial
- Patterns and Clinical Implications of Hemorrhagic Transformation After Thrombolysis in Acute Ischemic Stroke: Results From the ENCHANTED Study
- Smoking influences outcome in patients who had thrombolysed ischaemic stroke: the ENCHANTED study
- The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes
- Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target
- Twenty-Four-Hour Post-Thrombolysis NIHSS Score As the Strongest Prognostic Predictor After Acute Ischemic Stroke: ENCHANTED Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia
- Registry status
- Completed
Technical summary
Registry record NCT01422616. Randomized; single masking; primary purpose treatment. Start 2012-03 (actual); primary completion 2018-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
- Acronym
- ENCHANTED
- Condition
- Ischemic Stroke
- Condition
- High Blood Pressure
- Intervention (Drug)
- Low-dose rtPA
- Intervention (Drug)
- Standard-dose rtPA
- Intervention (Other)
- Intensive blood pressure (BP) lowering
- Intervention (Other)
- BP management policies
- Lead sponsor
- The George Institute
- Collaborator
- National Health and Medical Research Council, Australia
- Collaborator
- The Stroke Association, United Kingdom
- Collaborator
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Collaborator
- Takeda
Record details
- Record id
cardio:ct-nct01422616- Content hash
8e779d9f37fe3a559cfa3dda79c4cc1801065b2d9a5f97dbf64d466a7e6b987b